In what could mark a historic leap in medical science, researchers are now closer than ever to developing a CRISPR-based therapy capable of cutting the HIV virus directly out of a patient’s genome — ...
Scientists are nearing a breakthrough in using CRISPR gene-editing to eliminate HIV from human DNA. Early trials of EBT-101 ...
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and ...
HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through ...
CRISPR has increasingly gained popularity in its role with immunotherapy over the years. This short video introduces CRISPR as related to immunotherapy, as well as its capabilities now and into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback